Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
split-virion h1n1 vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The split-virion H1N1 vaccine refers to a class of inactivated influenza vaccines developed in response to the 2009 H1N1 pandemic. These vaccines are produced by disrupting the influenza virus (specifically the A/California/7/2009 strain) with detergents, resulting in 'split' viral particles that contain the hemagglutinin (HA) antigen. This method reduces reactogenicity compared to whole-virion vaccines while maintaining immunogenicity. Multiple manufacturers, including GSK (Pandemrix), Sanofi Pasteur (Humenza, Panenza), and several Chinese companies like Sinovac, produced these vaccines in both adjuvanted (e.g., with AS03) and non-adjuvanted forms. They were primarily administered via intramuscular injection to provide protective immunity against pandemic H1N1 influenza, commonly known as swine flu.
- Brand names
- PandemrixHumenzaPanenzaArepanrix
- Other names
- inactivated split-virion 2009 pandemic influenza a h1n1 vaccinemonovalent H1N1 vaccineswine flu vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on split-virion h1n1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on split-virion h1n1 vaccine.